Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016

  • ID: 3845350
  • Report
  • 47 pages
  • Global Markets Direct
1 of 6
Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016

Summary

‘Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016’, provides in depth analysis on Matrix Protein 1 (M1 or M) targeted pipeline therapeutics.

The report provides comprehensive information on the Matrix Protein 1 (M1 or M), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Matrix Protein 1 (M1 or M)
- The report reviews Matrix Protein 1 (M1 or M) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics and enlists all their major and minor projects
- The report assesses Matrix Protein 1 (M1 or M) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Matrix Protein 1 (M1 or M) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Matrix Protein 1 (M1 or M)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Matrix Protein 1 (M1 or M) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Matrix Protein 1 (M1 or M) Overview

Therapeutics Development

Matrix Protein 1 (M1 or M) - Products under Development by Stage of Development

Matrix Protein 1 (M1 or M) - Products under Development by Therapy Area

Matrix Protein 1 (M1 or M) - Products under Development by Indication

Matrix Protein 1 (M1 or M) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Unknown Stage Products

Matrix Protein 1 (M1 or M) - Products under Development by Companies

Matrix Protein 1 (M1 or M) - Products under Development by Universities/Institutes

Matrix Protein 1 (M1 or M) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Matrix Protein 1 (M1 or M) - Companies Involved in Therapeutics Development

Novavax, Inc.

Redbiotec AG

Sarepta Therapeutics, Inc.

Matrix Protein 1 (M1 or M) - Drug Profiles

(influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza (virus like particle, tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [serotype A] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (virus like particle, monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

radavirsen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SARS (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Matrix Protein 1 (M1 or M) - Featured News & Press Releases

Jul 30, 2015: Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP

Nov 17, 2014: Novavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP

Oct 29, 2014: U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M

Sep 30, 2014: Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate

Sep 23, 2014: Novavax H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M Delivers Positive Phase 1/2 Clinical Data

Mar 10, 2014: Novavax Reports Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M

Jul 29, 2013: Novavax Initiates First Phase 1 Clinical Trial of its A Influenza Vaccine Candidate

Jul 08, 2013: GenScript's Rush Gene Services Help Novavax Expedite 28-day Development of H7N9 Vaccine

Jul 08, 2013: Novavax Initiates First Phase 1 Clinical Trial of Its A(H7N9) Influenza Vaccine Candidate

May 10, 2013: Novavax's H7N9 VLP Influenza Vaccine Enters Animal Testing

Feb 27, 2013: Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA

Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100

Sep 10, 2012: Novavax Delays Testing On New Experimental Flu Vaccine

Jul 24, 2012: NOVAVAX Provides Update on Influenza Programs

Mar 30, 2012: AVI BioPharma To Present Preclinical Data From Influenza Study At 22nd European Congress Of Clinical Microbiology And Infectious Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Novavax, Inc., H2 2016

Pipeline by Redbiotec AG, H2 2016

Pipeline by Sarepta Therapeutics, Inc., H2 2016 25List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
Matrix Protein 1 (M1 or M) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Matrix Protein 1 (M1 or M) – Pipeline Review, H2 2016, outlays comprehensive information on the Matrix Protein 1 (M1 or M) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Matrix Protein 1 (M1 or M) M1 protein is a matrix protein of the influenza virus. It forms a coat inside the viral envelope. It plays critical roles in virus replication, entry and uncoating to assembly and budding of the virus particle. M1 binding to ribonucleocapsids (RNPs) in nucleus seems to inhibit viral transcription. The molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Novavax, Inc.
Redbiotec AG
Sarepta Therapeutics, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll